Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
The test, which is at the proof-of-concept stage, can rapidly screen a drop of blood for biomarkers of pancreatic cancer. It can provide results in less than an hour. The findings were published recently in the journal ACS Nano.
“An important step towards being able to cure diseases that come out of nowhere, like pancreatic cancer, is early detection,” said first author Jean Lewis, an assistant project scientist in the Department of Nanoengineering at UC San Diego. “We envision that in the future, physicians might perform this type of test using a quick finger stick to diagnose patients who may not know they have the disease yet.”
Blood tests for early cancer detection, known as liquid biopsies, are a hot topic in research. They have the potential to detect cancer early on without having to do invasive surgical procedures like tumor biopsies. To screen for pancreatic cancer in the blood, researchers are developing new methods that involve collecting and analyzing nano-sized biological structures called exosomes, which are released from all cells in the body, including cancer cells. Exosomes contain proteins and genetic material that can serve as biomarkers for detecting cancers.
But because exosomes are so tiny and fragile, they are hard to isolate from blood. Current methods to extract exosomes are time-consuming and require that blood samples be pretreated or diluted prior to use.
The test developed by UC San Diego researchers uses an electronic chip-based system to extract exosomes directly from blood in minutes. “We can use just a drop of blood as is—no extra processing required,” said Lewis. “We can also analyze the exosomes right there on the spot and show whether they carry any of the cancer biomarkers we are looking for.”
Lewis worked on this project as part of a cross-disciplinary collaboration between nanotechnology researchers at the UC San Diego Jacobs School of Engineering and clinicians at Moores Cancer Center at UC San Diego Health. The collaboration is led by Michael Heller, professor emeritus of nanoengineering at the UC San Diego Jacobs School of Engineering, who is now at Oregon Health & Science University’s Knight Cancer Institute.
“The innovation of this work is that it essentially combines all the complex, lengthy steps of sample preparation, exosome isolation and final assay interpretation required by other platforms into one seamless ‘sample-to-answer’ device,” said Heller. “We’ve developed a prototype platform that has the potential to translate into a handheld, rapid and relatively inexpensive point of care testing device for pancreatic cancer.”
It Only Takes a Drop
The test is simple. Apply a drop of blood on a small electronic chip, turn the current on, wait several minutes, add fluorescent labels and look at the results under a microscope. If a blood sample tests positive for pancreatic cancer, bright fluorescent circles will appear.
“This test could be used as a primary screening strategy to identify patients who would subsequently need to undergo more expensive and invasive diagnostic methods like a CT scan, MRI or endoscopy,” said Dr. Rebekah White, surgical oncologist and associate professor of surgery at Moores Cancer Center.
The chip used in this test works by applying an alternating electric current, which selectively pulls nano-sized particles like exosomes out of the blood and deposits them onto tiny electrodes on the chip’s surface. Larger blood particles get washed away while smaller ones such as exosomes are left behind. Researchers then apply fluorescently labeled antibodies that specifically target two protein biomarkers for pancreatic cancer: glypican-1 and CD63. If these biomarkers are present, brightly colored circles where the antibodies bind can be seen under a microscope, indicating a positive result. This entire process can be done in less than an hour.
So far, the team has only tested this system on a small sample set of patients. In an initial validation study on a group of 31 patients, the chip was able to flag the blood samples of 20 patients with pancreatic cancer from those of 11 patients without cancer.
Working Toward Early Detection
The team cautions that the biomarker levels screened in this study might not represent those in early stage cancer. “How small are these biomarker levels between stage 0 and stage 1 cancer? And how can we make our technology sensitive enough to detect these amounts? We’re doing more research to get a good handle on these questions,” said Heller.
Next steps also include studies on a larger sample size, screening more samples from patients at various stages of cancer, and optimizing and validating this technology for early cancer detection. “A challenge in doing these studies is getting hold of early stage blood samples, when patients don’t even know they have the disease yet,” said Lewis.
“Future work would entail obtaining blood samples from patients that have high risk factors for pancreatic cancer—new onset diabetes or a family history of it, smoking or obesity—and continue sampling their blood over an extended period of time. Of the patients that are subsequently diagnosed, we can go back and analyze their pre-diagnostic blood samples to see how early on we can detect cancer biomarkers,” said White.
The researchers are also exploring other blood-based biomarkers—in addition to glypican-1 and CD63—to improve this system’s accuracy and sensitivity for pancreatic cancer detection.
Learn more: New Blood Test Rapidly Detects Signs of Pancreatic Cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Canceron March 29, 2023 at 12:17 am
Pancreatic cancer is one of the most challenging cancers to treat, as it is often diagnosed at an advanced stage with typically poor outcomes to available therapies. The 5-year survival rate at ...
- Bolton's Amir Khan supports Pancreatic Cancer UK researchon March 28, 2023 at 9:15 pm
Amir Khan has spoken about the C-word after and the impact it has on the whole family after his mother was diagnosed with cancer. The retired Bolton boxer spoke to Pancreatic Cancer UK to front an ...
- Drummer Brandon Stone of 'The Nadas' diagnosed with pancreatic canceron March 28, 2023 at 8:34 pm
TODAY, THROUGH A POST ON THE WEBSITE CARING BRIDGE, BRANDON STONE OF THE NATA SAID HE BEGAN CHEMOTHERAPY AFTER BEING DIAGNOSED WITH PANCREATIC CANCER. HE SAYS HE RECEIVED THE UNEXPECTED HEALTH NEWS ...
- Pancreatic Cancer: Doctor Explains 7 Unusual Symptoms of This Silent Killeron March 28, 2023 at 7:36 pm
Pancreatic cancer is also known as the “silent disease” because there are not many noticeable symptoms early on.
- Cracking the Code: Unlocking Pancreatic Cancer Risk Factorson March 28, 2023 at 10:17 am
After analyzing lifestyle factors and medical conditions, researchers have uncovered potential areas for prevention and early diagnosis of pancreatic cancer.
- Researchers receive NCI grant to advance new treatment approach for pancreatic canceron March 28, 2023 at 9:42 am
Genel, Ph.D., have received a grant from the National Cancer Institute to advance a new treatment approach for pancreatic cancer.
- Hebrew University researchers discover how pancreatic cancer spreads through bodyon March 27, 2023 at 3:38 am
Study published in Nature holds out hope for patients by pointing to an existing drug that could undergo trials for use in fighting metastases ...
- Study on pancreatic cancer spread offers hope of improved treatmenton March 27, 2023 at 1:48 am
New understanding provides crucial information for those seeking better therapies for this often fatal form of cancer.
- VCP/p97 as a therapeutic target in KRAS-mutant pancreatic canceron March 24, 2023 at 11:26 am
A new research paper, titled "VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer," was published ...
via Bing News